-+ 0.00%
-+ 0.00%
-+ 0.00%

Rein Therapeutics releases scientific presentation on IPF candidate LTI-03

PUBT·09/04/2026 21:19:28
Listen to the news
Rein Therapeutics releases scientific presentation on IPF candidate LTI-03
  • Rein Therapeutics published a scientific presentation outlining its fibrosis pipeline, centered on inhaled IPF candidate LTI-03.
  • Deck highlights Phase 1b results: 5 mg, 10 mg doses tolerated over 14 days, no treatment-related serious adverse events.
  • Exploratory biomarker readouts showed nominal significance in 5 markers at 10 mg, 2 at 5 mg, aligned with preclinical findings.
  • Program update includes an enrolling Phase 2 RENEW trial for LTI-03 in IPF, listed as NCT06968845.
  • Presentation positions LTI-03 as a caveolin-1 scaffolding domain mimic with dual anti-fibrotic, epithelial-protective activity, delivered by dry powder inhaler.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief on September 04, 2026, and is solely responsible for the information contained therein.